Joannidis Michael
Crit Care. 2012 Nov 5;16(6):167. doi: 10.1186/cc11651.
In the continuing dispute about the superiority of either intermittent or continuous renal replacement therapy for the critically ill, hybrid methods such as sustained low-efficiency dialysis (SLED) combining the advantages of both modalities--that is, excellent hemodynamic stability and low costs--receive growing attention. The study by Schwenger and colleagues is the first randomized trial indicating that there may be no significant difference in survival at 90 days between patients treated with SLED as compared with those treated with continuous veno-venous hemofiltration.
在关于间歇性或连续性肾脏替代疗法对危重症患者谁更具优势的持续争论中，诸如持续低效透析（SLED）这种结合了两种模式优点（即出色的血流动力学稳定性和低成本）的混合方法受到越来越多的关注。施温格及其同事开展的这项研究是首个随机试验，表明接受SLED治疗的患者与接受连续性静脉-静脉血液滤过治疗的患者相比，90天生存率可能没有显著差异。
